An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME

Trial Profile

An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Nesvacumab (Primary) ; Aflibercept
  • Indications Age-related macular degeneration; Diabetic macular oedema
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 11 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Apr 2015 Planned number of patients changed from 60 to 20 as per ClinicalTrials.gov record.
    • 05 Apr 2015 Planned End Date changed from 1 Oct 2014 to 1 Oct 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top